Bert A 't Hart


Affiliation: Biomedical Primate Research Centre
Country: The Netherlands


  1. t Hart B. Reverse translation of failed treatments can help improving the validity of preclinical animal models. Eur J Pharmacol. 2015;759:14-8 pubmed publisher
    ..This seems a difficult task as the cause of failure is often not known. Here we propose a potentially useful strategy for investigating why a promising strategy fails as a guidance for improving the validity of the animal model(s). ..
  2. request reprint
    t Hart B, Van Meurs M, Brok H, Massacesi L, Bauer J, Boon L, et al. A new primate model for multiple sclerosis in the common marmoset. Immunol Today. 2000;21:290-7 pubmed
  3. t Hart B, Gran B, Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med. 2011;17:119-25 pubmed publisher
    ..We also discuss models that best reproduce specific aspects of MS pathology and how these can potentially improve preclinical selection of promising therapies from the discovery pipeline. ..
  4. t Hart B, Bogers W, Haanstra K, Verreck F, Kocken C. The translational value of non-human primates in preclinical research on infection and immunopathology. Eur J Pharmacol. 2015;759:69-83 pubmed publisher
  5. Jagessar S, Heijmans N, Blezer E, Bauer J, Weissert R, t Hart B. Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant. J Neuroinflammation. 2015;12:169 pubmed publisher
    ..Moreover, rhMOG contains pathogenic and regulatory epitopes, but the pathogenic hierarchy of rhMOG epitopes is strongly influenced by the adjuvant in which the protein is formulated. ..
  6. t Hart B. Why does multiple sclerosis only affect human primates?. Mult Scler. 2016;22:559-63 pubmed publisher
    ..Binding of the antibodies can cause BBB leakage and destabilization of the axon-myelin coupling. The ensuing cytodegeneration and release of self-antigens could be a start of the characteristic pathological features of MS. ..
  7. t Hart B, Hintzen R, Laman J. Multiple sclerosis - a response-to-damage model. Trends Mol Med. 2009;15:235-44 pubmed publisher
    ..This response-to-damage of antiviral memory cells can take place years after the initiating infection. Consequently, elucidating the anti-herpesvirus T-cell repertoire might provide new targets for preventive diagnosis and therapy. ..
  8. Jagessar S, Holtman I, Hofman S, Morandi E, Heijmans N, Laman J, et al. Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein. J Immunol. 2016;197:1074-88 pubmed publisher
  9. tHart B, Kap Y, Morandi E, Laman J, Gran B. EBV Infection and Multiple Sclerosis: Lessons from a Marmoset Model. Trends Mol Med. 2016;22:1012-1024 pubmed publisher

More Information


  1. request reprint
    t Hart B, Hintzen R, Laman J. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis. 2008;5:38-52 pubmed
    ..The promising effects during ongoing disease in a relevant preclinical IMID model illustrate the potential of these two antibodies as treatment of IMID, in particular for multiple sclerosis on which disease EAE has been modeled. ..
  2. t Hart B, Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol. 2009;68:341-55 pubmed publisher
    ..Moreover, this model provides new insights into possible pathogenetic mechanisms in MS. ..
  3. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015;17:135 pubmed publisher
    ..Presented results on preclinical pharmacological properties of ALX-0061 are supportive of clinical development in RA. ..
  4. Verheul M, Vierboom M, t Hart B, Toes R, Trouw L. Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. Arthritis Res Ther. 2017;19:246 pubmed publisher
    ..Rhesus monkeys develop anti-CarP antibodies upon induction of collagen-induced arthritis, while we were unable to detect RF or ACPA. Also, the development of anti-CarP antibodies could be inhibited by preventive abatacept treatment. ..
  5. Woo J, Vierboom M, Kwon H, Chao D, Ye S, Li J, et al. PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis Res Ther. 2013;15:R207 pubmed
    ..The activity of PDL241 in both in vitro and in vivo models highlights the potential of CD319 as a therapeutic target in RA. ..
  6. Vierboom M, Breedveld E, Kondova I, t Hart B. Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther. 2010;12:R200 pubmed publisher
    ..In response to this requirement we set out to develop a model of collagen-induced arthritis (CIA) in a small-sized nonhuman primate species (300 to 400 g at adult age); that is, the common marmoset (Callithrix jacchus)...
  7. t Hart B, Abbott D, Nakamura K, Fuchs E. The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov Today. 2012;17:1160-5 pubmed publisher
    ..In this Feature article we will highlight the common marmoset, a small-bodied nonhuman primate (NHP), as a useful model in biomedical and preclinical translational research. ..